Predicting the dose of vancomycin in ICU patients receiving different types of RRT therapy: a model-based meta-analytic approach.


Journal

British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323

Informations de publication

Date de publication:
06 2019
Historique:
received: 25 09 2018
revised: 28 01 2019
accepted: 10 02 2019
pubmed: 16 2 2019
medline: 14 4 2020
entrez: 16 2 2019
Statut: ppublish

Résumé

Previous pharmacokinetic (PK) studies have proposed various dosing regimens for vancomycin in intensive care unit (ICU) patients undergoing renal replacement therapy (RRT), but all are restricted to specific RRT modalities. To be useful in practice, a population PK model would need to predict vancomycin clearance during any RRT modality. Development of such a model is feasible using meta-analysis of published summarized estimates of vancomycin PK parameters. Our aims were: (i) to develop and validate a population PK model for vancomycin that takes into account any RRT modalities, and (ii) to predict vancomycin dosing for RRT patients in ICU. Vancomycin pharmacokinetics were assumed to be two-compartmental, total body clearance being the sum of non-RRT clearance and RRT-induced clearance. Drug disposition and non-RRT clearance parameters were estimated by systematic review and meta-analysis of previously published parameter estimates. The relationship between RRT-induced clearance and RRT flowrate settings was assessed using a model-based meta-analysis. Prediction performances of the PK model were assessed using external data. The meta-analyses of disposition parameters, non-RRT clearance and RRT-induced clearance included 11, 6 and 38 studies (84 RRT clearance measurements) respectively. The model performed well in predicting external individual PK data. Individual vancomycin concentrations during RRT were accurately predicted using Bayesian estimation based solely on pre-RRT measurements. The PK model allowed accurate prediction of the vancomycin pharmacokinetics during RRT in ICU patients. Based on the model of RRT-induced clearance, an appropriate adjustment of the vancomycin dosing regimen could be proposed for any kind of flowrate settings.

Identifiants

pubmed: 30768726
doi: 10.1111/bcp.13904
pmc: PMC6533443
doi:

Substances chimiques

Anti-Bacterial Agents 0
Vancomycin 6Q205EH1VU

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1215-1226

Informations de copyright

© 2019 The British Pharmacological Society.

Références

Clin Pharmacokinet. 2018 Nov;57(11):1435-1447
pubmed: 29512049
Fundam Clin Pharmacol. 2008 Dec;22(6):633-48
pubmed: 19049668
Clin Infect Dis. 2011 Feb 1;52(3):285-92
pubmed: 21217178
Pharm Res. 2006 Sep;23(9):2036-49
pubmed: 16906454
J Pharmacokinet Biopharm. 1998 Oct;26(5):581-93
pubmed: 10205772
Int J Antimicrob Agents. 2018 Aug;52(2):151-157
pubmed: 29526606
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
Br J Clin Pharmacol. 1999 Jul;48(1):9-13
pubmed: 10383553
Crit Care Med. 2014 Jul;42(7):1640-50
pubmed: 24674926
Intensive Care Med. 1993;19(6):347-50
pubmed: 8227726
Clin Pharmacol Ther. 2012 Sep;92(3):352-9
pubmed: 22760002
Int J Antimicrob Agents. 2014 Aug;44(2):163-7
pubmed: 24837847
CPT Pharmacometrics Syst Pharmacol. 2016 Feb;5(2):54-64
pubmed: 26933516
Crit Care. 2014 May 15;18(3):R99
pubmed: 24887569
Clin Nephrol. 2009 Oct;72(4):286-91
pubmed: 19825334
Clin Nephrol. 2012 Apr;77(4):329-31
pubmed: 22445477
J Antimicrob Chemother. 2013 Dec;68(12):2859-65
pubmed: 23800905
CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):288-297
pubmed: 29569841
Br J Clin Pharmacol. 2019 Jun;85(6):1215-1226
pubmed: 30768726
Stat Med. 2008 Dec 20;27(29):6072-92
pubmed: 18800342

Auteurs

Guillaume Claisse (G)

Service de Néphrologie, Dialyse, Transplantation Rénale, Hôpital Nord, Saint-Etienne, France.

Paul J Zufferey (PJ)

Unité de Recherche Clinique, Innovation, Pharmacologie, Hôpital Nord, Saint-Etienne, France.
Département d'Anesthésie-Réanimation, Hôpital Nord, Saint-Etienne, France.

Jane C Trone (JC)

Département de radiothérapie, Institut de Cancérologie Lucien Neuwirth, Saint Etienne, France.
INSERM, U1059, Dysfonction Vasculaire et Hémostase, Saint-Etienne, France.

Nicolas Maillard (N)

Service de Néphrologie, Dialyse, Transplantation Rénale, Hôpital Nord, Saint-Etienne, France.
Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Saint-Etienne, France.

Xavier Delavenne (X)

INSERM, U1059, Dysfonction Vasculaire et Hémostase, Saint-Etienne, France.

Silvy Laporte (S)

Unité de Recherche Clinique, Innovation, Pharmacologie, Hôpital Nord, Saint-Etienne, France.
INSERM, U1059, Dysfonction Vasculaire et Hémostase, Saint-Etienne, France.

Edouard Ollier (E)

Unité de Recherche Clinique, Innovation, Pharmacologie, Hôpital Nord, Saint-Etienne, France.
INSERM, U1059, Dysfonction Vasculaire et Hémostase, Saint-Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH